All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Tagrisso 80mg Tablet
Prescription Required
Salt Composition : Osimertinib
Manufacturer : ASTRAZENECA PHARMA INDIA LTD
Origin of Medicine : United Kingdom
10 Tablet(s) In A Strip
PAP Information : Buy 1, get 2 Free. Contact us for latest updates.
Program Overview: ASTRAZENECA PHARMA INDIA LTD, is dedicated to helping patients in need of Tagrisso 80mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 1 strip of Tagrisso 80mg tablets, and you will receive 2 additional strips of Tagrisso 80mg tablets. Therefore, if eligible, you will have to pay only Rs. 117,500 for 3 strips, which is Rs.39,167 per strip.
With MrMed's MRP discount of Rs. 34,170 per strip and Novartis’s PAP program, the overall savings is over 3.37 lakhs per purchase.
Eligibility Criteria: To qualify for the Tagrisso’s Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Osimertinib 80mg tablet from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by AstraZeneca can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Program Overview: ASTRAZENECA PHARMA INDIA LTD, is dedicated to helping patients in need of Tagrisso 80mg tablet. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 1 strip of Tagrisso 80mg tablets, and you will receive 2 additional strips of Tagrisso 80mg tablets. Therefore, if eligible, you will have to pay only Rs. 117,500 for 3 strips, which is Rs.39,167 per strip.
With MrMed's MRP discount of Rs. 34,170 per strip and Novartis’s PAP program, the overall savings is over 3.37 lakhs per purchase.
Eligibility Criteria: To qualify for the Tagrisso’s Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Osimertinib 80mg tablet from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by AstraZeneca can avail of it without having to purchase the medication from MrMed.
Introduction to Tagrisso 80mg Tablet
Tagrisso 80mg tablet contains the active substance Osimertinib. It is an antineoplastic drug that belongs to the class protein kinase inhibitor. It is used to treat adults with a type of lung cancer called non-small cell lung cancer. If a test has shown that your cancer has certain changes in a gene called EGFR (epidermal growth factor receptor), then your cancer will likely respond to treatment with this medicine.
Tagrisso 80mg tablet can be given to you after the complete removal of your cancer as a post-surgical adjuvant treatment. It can also be given as the first-line medication for cancer that has spread to other body parts. It is also used to treat certain types of NSCLC that have spread to other body parts in adults who could not be treated successfully with similar chemotherapy medications. Do not give this medicine to children or adolescents under the age of 18.
Do not take Tagrisso 80mg tablet if you are allergic to Osimertinib or any other ingredients of this medicine. Before initiating the treatment, inform your physician if you have kidney, heart, or eye problems and if you have suffered from lung inflammation. Report any symptoms of difficulty breathing together with a cough or fever, severe peeling of your skin, persistent fever, bleeding or bruising more easily, increased tiredness, pale skin, and infection.
Uses of Tagrisso 80mg Tablet
- Certain types of non-small cell lung cancer (NSCLC)
Therapeutic Effects of Tagrisso 80mg Tablet
Tagrisso 80mg tablet is a kinase inhibitor that works by blocking epidermal growth factor receptor (EGFR) and may help to slow or stop your lung cancer from growing. It may also help to reduce the size of the tumor and prevent the tumor from reoccurring again after being removed by the surgery.
Interaction of Tagrisso 80mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products. Certain medications may interact with the effects of Tagrisso 80mg tablet and reduce its effectiveness by causing undesirable side effects.
More Information about Tagrisso 80mg Tablet
- Store Tagrisso 80mg tablet at room temperature (25°C)
- keep the tablet away from the reach of children and pets.
- If you forgot to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.
- Do not take a double dose to make up a forgotten dose.
How to consume Tagrisso 80mg Tablet
Your doctor will decide the dose and duration of the treatment based on your disease condition, severity, and other factors. Take the tablets as prescribed by your doctor. Do not break, crush, split, or chew the tablets. Swallow the tablet whole with a glass of water. Take this medicine with or without food. If you cannot swallow the tablets, you can dissolve them as per your doctor's advice.
Safety Advices for Tagrisso 80mg Tablet
Pregnancy
Tagrisso 80mg tablet is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using an effective birth control method during the treatment and for 2 months after your last dose is necessary.
Breast Feeding
Breastfeeding is not recommended in patients taking Tagrisso 80mg tablet because the medicine passes into the breast milk in small amounts and may harm your baby.
Lungs
It is unknown whether Tagrisso 80mg tablet can be used in patients with other lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Tagrisso 80mg tablet is safe when administered in patients with liver diseases. Dose adjustments are not necessary for mild, moderate, or severe liver failure. Inform your physician if you have liver problems before initiating the therapy.
Alcohol
It is unknown whether it is safe to consume alcohol when taking Tagrisso 80mg tablet. Consult your doctor for more advice.
Driving
It doesn't affect your ability to drive or operate heavy machinery after taking Tagrisso 80mg tablet. Consult your doctor if you have faced any difficulties.
Side Effects of Tagrisso 80mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Common
- Low WBC and platelets
- Diarrhea, decreased appetite
- Anemia
- Rash
- Muscle and joint pain
- Nail changes
- Dry skin
- Tiredness
- Cough
- Inflamed and sore mouth
Serious
- Decreased heart function, irregular heartbeats
- Breathing difficulty together with a cough or fever
- Eye problems
- Anemia
- Skin lesions
Word of Advice
Tagrisso 80mg tablet may interact with oral contraceptives; hence discuss with your doctor the most appropriate method of contraception. If you are a male patient with a female partner of reproductive potential, use contraceptives during the treatment and for 4 months after the last dose. Your doctor will regularly do lab tests to check whether the medicine works. Do not breastfeed during the treatment with this medicine and for 2 weeks after your last dose. This medicine may impair fertility in females and males of reproductive potential; consult your doctor if you are planning for pregnancy.
FAQs
Q 1. What foods to avoid when taking Tagrisso 80mg tablet?
The effectiveness of the medication can be reduced by certain types of foods, such as grapefruit. Consult your doctor for more advice on diet and nutrition.
Q 2. What is the best time of day to take Tagrisso 80mg tablet?
Take Tagrisso 80mg tablet as advised by your doctor. Take the tablet at the same time every day. Swallow the tablet whole with water.
Q 3. Does Tagrisso 80mg tablet shrink tumors?
Tagrisso 80mg tablet has been shown to be effective at shrinking tumors in patients and slowing down the worsening of cancer.
Q 4. Can Tagrisso 80mg tablet be given to patients with kidney problems?
Tagrisso 80mg tablet is safe when prescribed to patients with kidney problems. No dose adjustments are necessary. Inform your physician if you have any kidney problems.
Q 5. Does Tagrisso 80mg tablet cause hair loss?
Although uncommon, Tagrisso 80mg tablet can cause hair loss. Consult your doctor if you have more hair fall.
Q 6. Can I take antibiotics with Tagrisso 80mg tablet?
Tagrisso 80mg tablet may interact with certain antibiotics and decrease the effectiveness of the medicine. Inform your physician about all the medicines, including over-the-counter medicines that you are taking or have taken before.
Fact Box of Tagrisso 80mg Tablet
Molecule name: Osimertinib | Therapeutic class: Antineoplastics |
Pharmacological class: Tyrosine kinase inhibitor | Indications: Treat non-small cell lung cancer (NSCLC) |
References
- TAGRISSO 80 mg film-coated tablets - Patient Information Leaflet (PIL) - (emc) [Internet]. www.medicines.org.uk. [Revised on July 2022] [cited 2023 Mar 28]. Available from: https://www.medicines.org.uk/emc/product/7615/pil
- Highlights Of Prescribing Information - Osimertinib. [revised on 2020] [cited 2023 Mar 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf
- Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
4000+ products
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
Secure Payment
100% secure and trusted payment protection
Easy Return
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.
